Security
NeuroSense Therapeutics Ltd. · NRSN
NRSNNASDAQCommon stockCurrentCIK 1875091Updated Oct 14, 2026
NRSN price & chart
Loading TradingView…
NASDAQ:NRSN on TradingView ↗About the company
NeuroSense Therapeutics is a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. The Company’s lead product candidate, PrimeC, is a novel oral therapy designed to target multiple key biological pathways underlying disease progression, including neuroinflammation, oxidative stress and dysregulated iron metabolism.
In the news
NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update News provided by NeuroSense Apr 24, 2025, 09:09 ET Share this article Share to X Share this article Share to X Letter outlines Phase 3 timeline for PrimeC in ALS, provides ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 1,028,000Source | 4,575,000Source | 3,185,000Source | 7,710,000Source |
| Property, Plant and Equipment, NetUSD | 58,000Source | 66,000Source | 85,000Source | 77,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 166,000Source | 3,378,000Source | 2,640,000Source | — |
| Assets, CurrentUSD | 778,000Source | 4,402,000Source | 2,916,000Source | — |
| Operating Lease, Right-of-Use AssetUSD | 170,000Source | 84,000Source | 162,000Source | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 2,588,000Source | 1,992,000Source | 4,944,000Source | 2,091,000Source |
| Stockholders’ equity: | ||||
| Retained Earnings (Accumulated Deficit)USD | -47,785,000Source | -36,660,000Source | -26,121,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | -1,560,000Source | 2,583,000Source | -1,759,000Source | — |
| Additional Paid in Capital, Common StockUSD | 46,225,000Source | 39,243,000Source | 24,362,000Source | — |
| Liabilities and EquityUSD | 1,028,000Source | 4,575,000Source | 3,185,000Source | — |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 2,516,000Source | 1,992,000Source | 3,459,000Source | — |
| Operating Lease, Liability, CurrentUSD | 98,000Source | 73,000Source | 69,000Source | — |
| Operating Lease, Liability, NoncurrentUSD | 72,000Source | — | 73,000Source | — |
| Additional Financial Items | ||||
| Restricted Cash and Investments, CurrentUSD | 47,000Source | 35,000Source | 40,000Source | — |
| TradeAndOtherCurrentPayablesUSD | — | — | 1,012,000Source | 475,000Source |
| TradeAndOtherReceivablesUSD | — | — | 236,000Source | 255,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossUSD | — | — | -11,280,000Source | -12,340,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 2,140,000Source | 557,000Source | 1,537,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -7,671,000Source | -10,135,000Source | -8,354,000Source | — |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -8,000Source | 1,000Source | 3,468,000Source | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | 8,000Source | 3,000Source | 29,000Source | — |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 4,432,000Source | 10,913,000Source | 3,975,000Source | — |
| Dividends paid | — | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 166,000Source | 3,378,000Source | 2,640,000Source | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 35,000Source | -41,000Source | 8,000Source | — |
| Additional Financial Items | ||||
| AdjustmentsForFinanceCostsUSD | — | — | 1,659,000Source | — |
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableUSD | — | — | 961,000Source | 459,000Source |
| AdjustmentsForSharebasedPaymentsUSD | — | — | 2,798,000Source | 5,105,000Source |
| Share-based Payment Arrangement, ExpenseUSD | 2,140,000Source | 557,000Source | 1,537,000Source | — |
| DepreciationUSD | 16,000Source | 22,000Source | 21,000Source | — |
| General and Administrative ExpenseUSD | 4,858,000Source | 4,204,000Source | 4,775,000Source | 7,136,000Source |
| Net Income (Loss) Attributable to ParentUSD | -11,125,000Source | -10,210,000Source | -10,107,000Source | — |
| Nonoperating Income (Expense)USD | -40,000Source | -308,000Source | 1,942,000Source | — |
| OtherAdjustmentsToReconcileProfitLossUSD | — | — | 87,000Source | 92,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -448,000Source | — |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | — | — | — | 79,000Source |
| Proceeds from Issuance of Common StockUSD | 7,000Source | — | — | — |
| ProceedsFromIssuingSharesUSD | — | — | 3,970,000Source | — |
| Proceeds from Stock Options ExercisedUSD | 22,000Source | — | 5,000Source | — |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesUSD | — | — | 80,000Source | 79,000Source |
| Restricted Cash and Investments, CurrentUSD | 47,000Source | 35,000Source | 40,000Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -11,085,000Source | -9,902,000Source | -12,049,000Source | — |
| Other Nonoperating Income (Expense)USD | — | — | -448,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -11,125,000Source | -10,210,000Source | -10,107,000Source | — |
| Earnings Per Share, BasicUSD per share | -0.44Source | -0.54Source | -0.74Source | — |
| Earnings Per Share, DilutedUSD per share | -0.44Source | -0.54Source | -0.74Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 25,481,343Source | 18,602,082Source | 13,640,168Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 25,481,343Source | 18,602,082Source | — | — |
| Additional Financial Items | ||||
| BasicEarningsLossPerShareUSD per share | — | — | -0.83Source | -1.07Source |
| Costs and ExpensesUSD | — | — | — | 77,000Source |
| DepreciationRightofuseAssetsUSD | — | — | 76,000Source | 77,000Source |
| DilutedEarningsLossPerShareUSD per share | — | — | -0.83Source | -1.07Source |
| ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilitiesUSD | — | — | — | 79,000Source |
| FinanceCostsUSD | — | — | 2,209,000Source | 45,000Source |
| FinanceIncomeUSD | — | — | 4,231,000Source | 1,257,000Source |
| General and Administrative ExpenseUSD | 4,858,000Source | 4,204,000Source | 4,775,000Source | 7,136,000Source |
| InterestExpenseOnLeaseLiabilitiesUSD | — | — | 11,000Source | 15,000Source |
| Nonoperating Income (Expense)USD | -40,000Source | -308,000Source | 1,942,000Source | — |
| Other ExpensesUSD | — | 23,000Source | — | — |
| Other General and Administrative ExpenseUSD | 466,000Source | 534,000Source | — | — |
| ProfessionalFeesExpenseUSD | — | — | 1,486,000Source | 1,085,000Source |
| ProfitLossFromOperatingActivitiesUSD | — | — | -13,302,000Source | -13,552,000Source |
| Research and Development ExpenseUSD | 6,227,000Source | 5,698,000Source | 7,274,000Source | — |
Offerings
Registration 333-293060
Filing attachments
ea030843601ex99-1.htm · 6-K · 2026-10-13
Exhibit 99.1 NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones Shares continue to trade on Nasdaq pending the Panel’s decision; minimum bid price compliance already regained Near-term catalysts include a New Drug Submission to Health Canada targeted for December 2026 and a decision on non-dilutive funding for the Phase 3 PARAGON trial expected in Q1 2027 CAMBRIDGE, Mass., Oct. 13, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN)…
Read attachment ↗ea030750101ex99-1.htm · 6-K · 2026-10-02
Exhibit 99.1 NeuroSense Provides Update on Nasdaq Listing Compliance Company regains compliance with Nasdaq’s minimum bid price requirement and intends to request a Nasdaq Hearings Panel hearing to seek additional time to regain compliance with the minimum market value requirement CAMBRIDGE, Mass., Oct. 2, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense” or the “Company”), a late-stage clinical biotechnology company focused on developing disease-modifying treatme…
Read attachment ↗ea030656401ex99-1.htm · 6-K · 2026-09-25
Exhibit 99.1 NeuroSense Provides Business Update and Progress for the First Half of 2026 CAMBRIDGE, Mass., September 25, 2026 -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense” or the “Company”), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today provided a business update with corporate highlights to date and financial results for the first half of 2026. NeuroSense is advancing PrimeC, its investigati…
Read attachment ↗ea030656401ex99-2.htm · 6-K · 2026-09-25
Exhibit 99.2 NeuroSense Therapeutics Ltd. Condensed Consolidated balance sheets U.S. dollars in thousands June 30, December 31, 2026 2025 ───────────────────────────────────────────────────────────────────…
Read attachment ↗ea030197401ex99-1.htm · 6-K · 2026-08-13
Exhibit 99.1 NeuroSense Issues CEO Letter to Shareholders CAMBRIDGE, Mass., August 13, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today releases a letter from the CEO, Alon Ben-Noon, to investors. Dear Fellow Shareholders, I wanted to take this opportunity to update you on NeuroSense’s preparations for the Phase 3 PARAGON study, …
Read attachment ↗ea030091501ex99-1.htm · 6-K · 2026-08-06
Exhibit 99.1 NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada Final meeting minutes reflect alignment with Health Canada on the planned content and structure of the ALS submission CAMBRIDGE, Mass., Aug. 6, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced that it is t…
Read attachment ↗